Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06187103
Other study ID # VAR-2023-05
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date May 2025

Study information

Verified date April 2024
Source Varian, a Siemens Healthineers Company
Contact Sean Davidson
Phone 437-991-8294
Email sean.davidson@varian.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any changes that may have occurred since the initial planning. Conventional CBCT technology is, however, limited by several factors including long acquisition times that result in motion artifacts in the image, smaller fields of view that limit the volume of anatomy that can be imaged, poor image quality that limits soft tissue visibility, and artifacts created by dense metal implants. This study will evaluate a novel CBCT imaging solution ("HyperSight") that has the potential to address the challenges of conventional CBCT.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date May 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient is willing and able to provide written consent. 2. Patient is at least 18 years of age at the time of consent. 3. Patient has biopsy confirmed malignancy and recommendation for definitive or palliative radiation to the head and neck, breast, lungs, upper GI structures, or pelvis. 4. Patient has ECOG performance status 0-2. 5. Patient will be receiving radiation therapy at University of Maryland Medical Center, Department of Radiation Oncology. Exclusion Criteria: 1. Patient is pregnant or attempting pregnancy. 2. Patient has implanted cardiac devices or nerve stimulation devices. 3. Patient has known genetic pre-disposition for sensitivity to radiation (e.g., Li Fraumeni). 4. Patient receives palliative radiation for 5 or fewer fractions. 5. Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response"). This includes prisoners.

Study Design


Intervention

Device:
HyperSight Imaging
Patients undergo 2 HyperSight CBCT acquisitions in addition to the standard imaging for treatment guidance. The HyperSight CBCT images will be acquired at the start of treatment, and approximately halfway through treatment. If the patient is sent for mid-treatment re-planning, a third HyperSight CBCT will be acquired on the same day as their re-simulation.

Locations

Country Name City State
United States University of Maryland Medical Center Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Varian, a Siemens Healthineers Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning. To evaluate the feasibility of HyperSight CBCT as a method for CBCT-based re-planning by measuring the fraction of patients whose HyperSight imaging meets criteria for potential CBCT-based treatment planning using HyperSight CBCT. The criteria include visibility of all key anatomical structures, image quality sufficient to contour anatomical structures, and clinically acceptable dose accuracy. 1 year
Secondary Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning by anatomical site To break down the fraction of patients that meet criteria for potential CBCT-based treatment planning using HyperSight CBCT by anatomical site (head/neck, breast, lungs, upper GI tract, and pelvis). 1 year
Secondary Image noise To evaluate the imaging noise in HyperSight CBCT using clinical images and to compare this aspect of image quality to conventional CBCT and simulation CT images. 1 year
Secondary Image low-contrast resolution To evaluate contrast between adjacent anatomical structures in HyperSight CBCT using clinical images and to compare this aspect of image quality to conventional CBCT and simulation CT images. 1 year
Secondary Image contrast-to-noise ratio To measure the contrast-to-noise ratio of HyperSight CBCT using clinical images and to compare this aspect of image quality to conventional CBCT and simulation CT images. 1 year
Secondary Qualitative assessment of motion artifacts To evaluate the severity of motion artifacts observed in HyperSight CBCT using clinical images and to compare motion artifacts to conventional CBCT and simulation CT. Qualitative assessments will be performed by independent observers using a 5-point Likert scale. 1 year
Secondary Qualitative assessment of metal artifacts To evaluate the severity of metal artifacts observed in HyperSight CBCT in head & neck patients with dental fillings and pelvis patients with hip prostheses and compare metal artifacts between HyperSight CBCT, conventional CBCT, and simulation CT. Qualitative assessments will be performed by independent observers using a 5-point Likert scale. 1 year
Secondary Comparison of anatomical structure contours defined on HyperSight and conventional imaging. To evaluate concordance of target volumes and critical organs at risk contoured on HyperSight and conventional CBCT imaging compared to anatomical structures contoured on simulation CT. Concordance will be measured using the Dice Similarity Coefficient and Hausdorff Distance. 1 year
Secondary Breath hold tolerance To evaluate the tolerance of breath-hold duration for patients with breast, thoracic, and upper GI malignancies between conventional and HyperSight CBCT imaging. 1-9 weeks
Secondary Patient experience of HyperSight imaging To evaluate patient experience of HyperSight imaging compared to conventional CBCT imaging. Patients will be asked to fill out a questionnaire. Questions will use a 5-point Likert scale. 1-9 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2